Skip to main content
Premium Trial:

Request an Annual Quote

Horizon CombinatoRx Contracts with Otsuka for Screening of Drug Candidates

NEW YORK (GenomeWeb) – Horizon Discovery today announced that its CombinatoRx division has entered into a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development.

Horizon CombinatoRx will receive $835,000 for the work, which is to be substantially completed by the end of the year.

Horizon acquired CombinatoRx from Zalicus in June for about $8 million. CombinatoRx's Combination High-Throughput Screening platform and Chalice analytics software enables the screening and analysis of thousands of complementary drug combinations. Combined with Horizon's Genesis gene editing platform and X-MAN isogenic cell line technology, the company provides services that include new phenotypic cell-based screens with compound siRNA, shRNA, and sgRNA libraries.

"As combination therapies emerge as the standard of care in a range of indications, it is important that we identify effective multi-target mechanisms," Edwin Rock, senior director of global clinical development for OPDC, said in a statement. "Using the Horizon CombinatoRx platform to explore our clinical stage programs in the context of combinations may provide us with information to guide development."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.